Dr. Reddy's Laboratories launches Toripalimab in India, a groundbreaking treatment for metastatic and recurrent ...

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India.

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

With this launch, India has become the third country in the world, after China and the US, to receive access to this ...

News on Telangana Today, Metastatic nasopharyngeal carcinoma (RM-NPC) latest news, Metastatic nasopharyngeal carcinoma (RM-NPC) news, | Telangana Today ...

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for ...

Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved ...

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab ...

Dr. Reddy’s Laboratories has launched Toripalimab, a New Biological Entity (NBE) in the domestic market. “The launch of ...

Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. This drug is designed to treat adults suffering ...

Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, ...